[go: up one dir, main page]

AR020323A1 - Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos - Google Patents

Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos

Info

Publication number
AR020323A1
AR020323A1 ARP990102313A ARP990102313A AR020323A1 AR 020323 A1 AR020323 A1 AR 020323A1 AR P990102313 A ARP990102313 A AR P990102313A AR P990102313 A ARP990102313 A AR P990102313A AR 020323 A1 AR020323 A1 AR 020323A1
Authority
AR
Argentina
Prior art keywords
group
amino
substituted
alkyl
mono
Prior art date
Application number
ARP990102313A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR020323(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR020323A1 publication Critical patent/AR020323A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polymerisation Methods In General (AREA)

Abstract

Preparaciones farmacéuticas que incluyen derivados del ácido 4-amino-3-sustituido-butanoico, que son efectivos para bloquear los grupos aminoy carboxilo, y un aminoácido alfa para obtener una estabilidad superior en almacenamiento, no solo en laform a de solucion sino también en estadosolido. Dichos derivados comprenden preferentemente gabapentina, pregabalina, bacolofeno y otros. Una preparacion farmacéutica estabilizada, con underivado del ácido 4-amino-3-sustituido-butanoico de formula(1), d onde R1 es un átomo de hidrogeno, un grupo hidroxilo, un grupo metilo o un grupo etilo;R2 es un grupo monovalente seleccionado a partir de: un grupo alquilo recto o ramificado C3-8; un grupo alquileno recto o ramificado C3-8; ungrupo alquilorecto o ramificado C3-8 que es mono- o di-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupo oxo, un grupo carboxilo o un grupo carboalcoxi;un grupo cicloalquilo C3-8; ungrupo cicloalquilo C3-8 que es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupo hidroxilo, un grupo alquilo, un grupoalcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, ungrupo ox o, un grupo carboxil o un grupo carboalcoxi; un grupo de anillo condensado formadopor orto-fusion de un anillo fenilo con un grupo cicloalquilo C4-8; un grupo de anillo condensado formado por orto-fusion de un anillo fenilocon un grupocicloalquilo C 4-8 donde dicho anillo fenilo es mono-, di- o tri-sustituido con un átomo de halogeno, un grupo trifluorometilo, un grupohidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio, un grupo amino, un grupo nitro, un grupocarboxilo o un grupo c arboalcoxi; un grupo de anillocondensado formado por orto-fusion de un anillo fenilo con un grupo cicloalquenilo C5-8 o un grupo cicloalcanodienilo C5-8 donde dicho anillo es mono-,di-, o tri-sustituido con un átomo dehalogeno, un grupo trifluoromet ilo, un grupo hidroxilo, un grupo alquilo, un grupo alcoxi, un grupo alquiltio,
ARP990102313A 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos AR020323A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13311398 1998-05-15

Publications (1)

Publication Number Publication Date
AR020323A1 true AR020323A1 (es) 2002-05-08

Family

ID=15097118

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102313A AR020323A1 (es) 1998-05-15 1999-05-14 Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos

Country Status (36)

Country Link
US (1) US7309719B1 (es)
EP (1) EP1077692B1 (es)
JP (1) JP4612923B2 (es)
KR (1) KR100602047B1 (es)
CN (1) CN1303991C (es)
AR (1) AR020323A1 (es)
AT (1) ATE271864T1 (es)
AU (1) AU768277B2 (es)
BR (1) BR9910508B1 (es)
CA (1) CA2327285C (es)
CO (1) CO5021224A1 (es)
CR (1) CR6026A (es)
CU (1) CU23253B7 (es)
DE (1) DE69918977T2 (es)
DK (1) DK1077692T3 (es)
EG (1) EG26803A (es)
ES (1) ES2221385T3 (es)
GT (1) GT199900069A (es)
HN (1) HN1999000072A (es)
HU (1) HU228771B1 (es)
ID (1) ID27724A (es)
IL (2) IL139298A0 (es)
IS (1) IS2233B (es)
MY (1) MY157878A (es)
NO (1) NO328959B1 (es)
NZ (1) NZ508015A (es)
PA (1) PA8472801A1 (es)
PE (1) PE20000556A1 (es)
PL (1) PL204921B1 (es)
PT (1) PT1077692E (es)
SI (1) SI1077692T1 (es)
SV (1) SV1999000064A (es)
TW (1) TWI243054B (es)
UY (1) UY25512A1 (es)
WO (1) WO1999059573A1 (es)
ZA (1) ZA200006484B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
DK1289364T3 (da) * 2000-06-16 2004-04-13 Teva Pharma Stabil gapapentin som indeholder mere end 20 ppm chlorioner
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
PL363155A1 (en) * 2000-06-16 2004-11-15 Teva Pharmaceutical Industries, Ltd. Stable gabapentin having ph within a controlled range
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
JP2004534764A (ja) * 2001-05-25 2004-11-18 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 液状医薬組成物
WO2005074895A1 (en) * 2004-02-04 2005-08-18 Alembic Limited Extended release coated microtablets of venlafaxine hydrochloride
CA2565095A1 (en) * 2004-05-17 2005-12-08 William S. Brusilow Decreasing brain neuronal glutamate levels using alpha-keto branched chain amino acids
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
DE102007019071A1 (de) 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
FR2918567B1 (fr) * 2007-07-11 2012-08-03 Pf Medicament Composition pharmaceutique stable d'un sel hydrosoluble de vinorelbine.
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
DK3192500T3 (da) 2009-05-19 2020-12-21 Neuroderm Ltd Sammensætninger til kontinuerlig indgivelse af dopa-decarboxylasehæmmere
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
TR201005241A1 (tr) 2010-05-25 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Kontrollü salım sağlayan pregabalin solüsyon formülasyonu.
EP2389934A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Tablet Formulations of Pregabalin
EP2389933A1 (en) 2010-05-25 2011-11-30 Sanovel Ilac Sanayi ve Ticaret A.S. Controlled-Release Pregabalin Compositions
EP3326615B1 (en) 2010-11-15 2020-01-08 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
CN107693486A (zh) 2012-06-05 2018-02-16 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
CN103494796B (zh) * 2013-09-30 2016-01-20 浙江华义医药有限公司 普瑞巴林稳定的药物组合物及其制备方法
US20160338949A1 (en) 2014-01-28 2016-11-24 Sun Pharmaceutical Industries Limited Stabilized gastroretentive tablets of pregabalin
HRP20201948T1 (hr) 2014-03-13 2021-01-22 Neuroderm Ltd Pripravci inhibitora dopa-dekarbokilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP2923694B1 (en) * 2014-03-27 2018-11-14 Sanovel Ilac Sanayi ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
EP2929878A1 (en) * 2014-04-09 2015-10-14 Arven Ilac Sanayi ve Ticaret A.S. Extended release formulations of gabapentin
CN107920987A (zh) 2015-05-26 2018-04-17 艾萨·欧蒂迪 控制延缓释放普瑞巴林
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
EP3861993A4 (en) 2018-10-04 2022-06-29 MEDRx Co., Ltd. Preparation stabilized by means of nonaqueous solvent
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
WO2021079887A1 (ja) 2019-10-25 2021-04-29 国立大学法人京都大学 タウオパチーの予防又は治療剤
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
CN112843015A (zh) * 2021-04-08 2021-05-28 海南鑫开源医药科技有限公司 一种加巴喷丁胶囊制剂及其制备方法
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
GB8311804D0 (en) * 1983-04-29 1983-06-02 Merrell Toraude & Co Treatment of seizure disorders and pharmaceutical compositions
US4595697A (en) * 1984-03-28 1986-06-17 Merrell Dow Pharmaceuticals Inc. Treatment of seizure disorders and pharmaceutical compositions useful therein
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
US5084479A (en) 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
HUT59656A (en) * 1990-11-15 1992-06-29 Puetter Medice Chem Pharm Process for producing s/+/-phenyl-alkanoic acids and alpha-amino-acids containing complexes and pharmaceutical compositions containing them as active components
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
JPH0597703A (ja) * 1991-10-04 1993-04-20 Yamanouchi Pharmaceut Co Ltd 改変型組織プラスミノーゲン活性化因子含有組成物
HU222776B1 (hu) * 1992-05-20 2003-10-28 Northwestern University (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása
US5629008A (en) * 1992-06-02 1997-05-13 C.R. Bard, Inc. Method and device for long-term delivery of drugs
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5248678A (en) * 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
US5260337A (en) * 1992-07-29 1993-11-09 Merck & Co., Inc. Ibuprofen-muscle relaxant combinations
JP3467794B2 (ja) * 1993-03-09 2003-11-17 日本油脂株式会社 学習能向上剤
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
JPH0867636A (ja) * 1994-08-30 1996-03-12 Yamanouchi Pharmaceut Co Ltd 播種性血管内凝固症候群（ｄｉｃ）の予防治療薬
GB9420784D0 (en) * 1994-10-14 1994-11-30 Glaxo Group Ltd Medicaments
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JPH1017476A (ja) * 1996-06-28 1998-01-20 Nippon Seiyaku Kk 敗血症用非経口製剤及びそれによる予防及び治療方法
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
CN1094757C (zh) * 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ－氨基丁酸及其衍生物
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
IT1311984B1 (it) * 1999-03-26 2002-03-22 Bioindustria Lab Italiano Medi Procedimento per la preparzione di gabapentin.
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6979462B1 (en) * 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen

Also Published As

Publication number Publication date
BR9910508B1 (pt) 2012-01-24
DE69918977D1 (de) 2004-09-02
WO1999059573A1 (en) 1999-11-25
UY25512A1 (es) 1999-07-19
SV1999000064A (es) 2000-03-31
CU23253B7 (es) 2007-12-17
EP1077692B1 (en) 2004-07-28
JP4612923B2 (ja) 2011-01-12
HUP0102022A3 (en) 2002-11-28
DE69918977T2 (de) 2005-07-28
PL344218A1 (en) 2001-10-08
NO20005768L (no) 2000-11-14
CA2327285C (en) 2005-06-14
ZA200006484B (en) 2002-02-11
PT1077692E (pt) 2004-12-31
CA2327285A1 (en) 1999-11-25
HUP0102022A2 (hu) 2001-11-28
CO5021224A1 (es) 2001-03-27
AU4073599A (en) 1999-12-06
CR6026A (es) 2008-08-26
AU768277B2 (en) 2003-12-04
IS5666A (is) 2000-10-16
SI1077692T1 (en) 2004-10-31
CN1303991C (zh) 2007-03-14
KR20010043611A (ko) 2001-05-25
IL139298A0 (en) 2001-11-25
HU228771B1 (en) 2013-05-28
WO1999059573A9 (en) 2000-05-04
CN1301155A (zh) 2001-06-27
ES2221385T3 (es) 2004-12-16
NO328959B1 (no) 2010-06-28
JP2000034226A (ja) 2000-02-02
TWI243054B (en) 2005-11-11
GT199900069A (es) 2000-11-04
IL139298A (en) 2009-07-20
US7309719B1 (en) 2007-12-18
PE20000556A1 (es) 2000-08-10
HN1999000072A (es) 2000-06-05
MY157878A (en) 2016-07-29
BR9910508A (pt) 2001-01-02
PL204921B1 (pl) 2010-02-26
IS2233B (is) 2007-04-15
NO20005768D0 (no) 2000-11-14
ID27724A (id) 2001-04-26
KR100602047B1 (ko) 2006-07-19
HK1036586A1 (en) 2002-01-11
NZ508015A (en) 2003-11-28
PA8472801A1 (es) 2001-12-14
EG26803A (en) 2014-09-21
EP1077692A1 (en) 2001-02-28
DK1077692T3 (da) 2004-12-06
ATE271864T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
AR020323A1 (es) Preparaciones farmaceuticas estabilizadas que contienen derivados de acido 4-amino-3-substituido butanoico y proceso para prepararlos
RU2290946C2 (ru) Амиды фумаровой кислоты
ATE510852T1 (de) Dermopharmazeutisch und kosmetisch wirksame oligopeptide
BR9914451A (pt) Composto de oxazol, processo para sua preparação, composição farmacêutica compreendendo dito composto, uso da composição e métodos de tratamento
AR063528A1 (es) Peptidos inhibidores de la exocitosis neuronal
DE122009000040I2 (de) Naphthalin-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen.
NO173446C (no) Analogifremgangsmaate til fremstilling av nye, terapeutisk aktive, substituerte alkandifosfonsyrer
ES2083123T3 (es) Nuevos derivados de aril-etil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR072610A1 (es) Composiciones para el tratamiento del dolor y/o la inflamacion
FI80877B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening.
MX9102241A (es) Analogos de gaba y de acido l-glutamico para tratamiento contra ataques.
ATE17242T1 (de) Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
ES2012467B3 (es) Compuesto de embulsion del tipo o/w
KR940008681A (ko) 디클로페낙 염용 비경구 용액
AR020016A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen, uso de los mismos para preparar un medicamento
PT92378A (pt) Processo para a preparacao de derivados de cromano, activos sobre o sistema nervoso central
KR910006241A (ko) 피리미딘-4,6-디카복실산 디아미드, 이의 제조방법, 이의 용도 및 이들 화합물을 기초로 하는 약제
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
RU2019118696A (ru) Фармацевтические композиции, содержащие инсулин
ES2071699T3 (es) Ariloxifenilpropilaminas, su preparacion y empleo.
McLamore et al. The Structure and Synthesis of a New Thiazolidone ANTIBIOTIC1
DK0667864T3 (da) Tricykliske forbindelser med farmaceutisk virkning
ES8608476A1 (es) Procedimiento de preparacion de nuevos derivados a-etilben- zol con un grupo dialquilaminoalcoxi sustituido y de sus sa-les de adicion acidas y amonicas cuaternarias
ZA944727B (en) Phosphonic acid compounds processes for preparing them and pharmaceutical compositions containing them
KR950700233A (ko) 아미노산 유도체 및 항활성산소제(Amino acid derivatives and anti-active oxygen agents)

Legal Events

Date Code Title Description
FG Grant, registration